Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Melissa G OoiNicholas Mitsiades

Abstract

p53 is inactivated in many human malignancies through missense mutations or overexpression of the human homologue of Mdm2 (Hdm2), an E3 ubiquitin ligase that ubiquitinates p53, thereby promoting its proteasomal degradation. The cis-imidazoline nutlin-3 can disrupt the p53-Hdm2 interaction and activate p53, inducing apoptosis in vitro in many malignancies, including multiple myeloma (MM). We hypothesized that suppression of Hdm2-mediated p53 ubiquitination may augment sequelae of p53 accumulation caused by proteasomal inhibition. We compared the response of MM cells versus several epithelial cancer models to the proteasome inhibitor bortezomib in combination with nutlin-3. The combination of sublethal concentrations of bortezomib plus nutlin-3 induced additive cytotoxicity against bortezomib-sensitive MM cell lines. Importantly, however, in breast, prostate, colon, and thyroid (papillary, follicular, anaplastic, and medullary) carcinoma cell lines, this combination triggered synergistic cytotoxicity, and increased expression of p53, p21, Hdm2, Bax, Noxa, PUMA, and cleavage of caspase-3 and poly ADP ribose polymerase. Coculture with bone marrow stromal cells attenuated MM cell sensitivity to nutlin-3 monotherapy and was associate...Continue Reading

References

Jul 1, 1993·Genes & Development·X WuA J Levine
Jan 9, 1999·The Journal of Biological Chemistry·A VassilevF M Uckun
Jul 21, 2001·Molecular Cell·J YuB Vogelstein
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Nicholas MitsiadesKenneth C Anderson
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Aug 5, 2003·Molecular and Cellular Biology·Timothy F BurnsWafik S El-Deiry
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Aug 3, 2004·Nature Medicine·Bert Vogelstein, Kenneth W Kinzler
Nov 16, 2004·Cancer Cell·Constantine S MitsiadesKenneth C Anderson
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Oct 20, 2005·Blood·Constantine S MitsiadesKenneth C Anderson
Jan 31, 2006·Proceedings of the National Academy of Sciences of the United States of America·Christian TovarLyubomir T Vassilev
Nov 1, 2006·Current Drug Targets·Constantine S MitsiadesKenneth C Anderson
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Jun 23, 2009·Cell Death and Differentiation·J T Lee, W Gu

❮ Previous
Next ❯

Citations

Apr 2, 2011·The Journal of Biological Chemistry·Brittany CrossJiandong Chen
Mar 28, 2013·Journal of Hematology & Oncology·Manujendra N SahaHong Chang
May 15, 2012·Haematologica·Lauren I Aronson, Faith E Davies
Nov 1, 2013·Nucleic Acids Research·Dongmei BaiXiaofeng Zheng
Jan 15, 2014·Cellular and Molecular Life Sciences : CMLS·Chiara GaspariniGiorgio Zauli
Dec 12, 2012·Expert Review of Hematology·Kevin D BoydFaith E Davies
Oct 19, 2013·Seminars in Oncology·Panisinee LawasutConstantine S Mitsiades
May 16, 2013·Current Problems in Surgery·Judy JinChristopher R McHenry
Jun 26, 2012·Seminars in Hematology·James J Driscoll, E Steve Woodle
Jan 29, 2014·Clinical Lymphoma, Myeloma & Leukemia·Eman M SewifySahar A El Gammal
Apr 27, 2010·Clinical Oncology : a Journal of the Royal College of Radiologists·R C Smallridge, J A Copland
Feb 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jürgen SonnemannJames F Beck
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Constantine S Mitsiades
Jan 5, 2018·The Journal of Clinical Endocrinology and Metabolism·Poyil PratheeshkumarKhawla S Al-Kuraya
Oct 28, 2017·Journal of Hematology & Oncology·Jahangir AbdiHong Chang
Jan 26, 2010·Journal of Experimental & Clinical Cancer Research : CR·Xiang LingFengzhi Li
Jan 29, 2019·Journal of Molecular Cell Biology·Marcus J G W Ladds, Sonia Laín
Dec 24, 2015·Oncotarget·Susanne LubEls Van Valckenborgh
Jan 30, 2019·Annual Review of Medicine·Chutima Kunacheewa, Robert Z Orlowski
Aug 12, 2017·Experimental & Molecular Medicine·Dong Min LeeKyeong Sook Choi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.